B
B. Telivala
Publications - 6
Citations - 3
B. Telivala is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 2 citations.
Papers
More filters
Journal ArticleDOI
CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
Scott N. Gettinger,T. Beck,X. Yang,B. Telivala,Daniel Morgensztern,Vamsidhar Velcheti,S.S. Ramalingam,Kurt A. Schalper,M. Dajee,A. Ranck,R. Yang,David R. Spigel +11 more
Journal ArticleDOI
Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS
Meghan Sri Karuturi,Gabrielle B. Rocque,Joseph C. Cappelleri,Joanne L. Blum,Steven McCune,B. Telivala,Sobha Kurian,Daniel M. Anderson,Michaela L. Tsai,Timothy J. Pluard,John Migas,Yao Wang,Monica Z. Montelongo,Debu Tripathy +13 more
TL;DR: Palbociclib treatment did not have any significant adverse impact on QoL in patients with HR+/HER2- ABC as assessed by QLQ-C30 functioning and symptom scales, and a similar trend across time was observed with the symptom scales.
Journal ArticleDOI
Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.
Michael A. Kolodziej,Lavi Kwiatkowsky,Patrick M. Travis,Sibel Blau,Sejal S. Kuthiala,B. Telivala,Geoffrey Calkins,Christina M. Parrinello +7 more
TL;DR: In this article , the authors examined ePRO reports submitted by patients using a proprietary commercially available ePRO tool, and found that patients receiving < 6 months of therapy were more likely to report severe symptoms during this time period as compared to those on treatment for 6 months or longer.
Journal ArticleDOI
2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
Scott N. Gettinger,Michael Schenker,J. De Langen,Juergen R. Fischer,Daniel Morgensztern,T. Ciuleanu,Thaddeus Beck,Javier de Castro Carpeño,Christian Schumann,X. Yang,B. Telivala,Koen Deschepper,Ernest Nadal,Kurt A. Schalper,Thomas Spires,David Balli,A Nassar,Samer Karam,Abhilasha Bhingare,David Spiegel +19 more
TL;DR: The CheckMate 592 (NCT03001882) trial as mentioned in this paper explored the association of biomarkers with efficacy of 1L NIVO + IPI in patients with mNSCLC.
Journal ArticleDOI
Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS
Debu Tripathy,Zhe Zhang,Joanne L. Blum,Meghan Sri Karuturi,Steven McCune,B. Telivala,Shailendra Lakhanpal,Kamal Patel,Richard G. Frank,Kit Lu,Chetan Deshpande,Yao Wang,Yuan Liu,Aditya Bardia +13 more
TL;DR: Early changes in ctDNA mutations were significantly associated with disease progression among patients with HR+/HER2- ABC receiving palbociclib, and the clinical utility of ct DNA-guided “adaptive” early therapeutic interventions to improve outcomes in patients with metastatic breast cancer was evaluated.